Mother-infant antidepressant concentrations, maternal depression, and perinatal events

Journal of Clinical Psychiatry

Volumn 72, Issue 7, 2011, Pages 994-1001

  Sit, Dorothy ^a   Perel, James M ^a   Wisniewski, Stephen R ^b   Helsel, Joseph C ^a   Luther, James F ^b   Wisner, Katherine L ^a  

^a UNIVERSITY OF PITTSBURGH   (United States)

^b UNIVERSITY OF PITTSBURGH GRADUATE SCHOOL OF PUBLIC HEALTH   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

AMFEBUTAMONE; ANTIDEPRESSANT AGENT; CITALOPRAM; ESCITALOPRAM; FLUOXETINE; FLUVOXAMINE; FLUVOXAMINE MALEATE; NORTRIPTYLINE; SEROTONIN UPTAKE INHIBITOR; SERTRALINE; VENLAFAXINE;

ADULT; ARTICLE; CLINICAL ARTICLE; CONTROLLED STUDY; DELIVERY; DEPRESSION; DRUG BLOOD LEVEL; DRUG HALF LIFE; DRUG SUBSTITUTION; DRUG WITHDRAWAL; FEMALE; GESTATIONAL AGE; HUMAN; MAJOR DEPRESSION; MATERNAL DEPRESSION; MATERNAL DISEASE; MOTHER CHILD RELATION; NEWBORN; PERINATAL PERIOD; PERIPARTUM EVENTS SCALE; PREGNANCY; PREGNANCY OUTCOME; PREMATURE LABOR; PRENATAL DRUG EXPOSURE; PRIORITY JOURNAL; SCORING SYSTEM; STRUCTURED CLINICAL INTERVIEW FOR DSM DISORDERS; UMBILICAL CORD BLOOD; UNITED STATES;

ADULT; ANTIDEPRESSIVE AGENTS; ANTIDEPRESSIVE AGENTS, TRICYCLIC; DEPRESSIVE DISORDER, MAJOR; DOSE-RESPONSE RELATIONSHIP, DRUG; FEMALE; FETAL BLOOD; FLUOXETINE; HUMANS; INFANT, NEWBORN; MATERNAL-FETAL EXCHANGE; NORTRIPTYLINE; OBSTETRIC LABOR, PREMATURE; PERSONALITY INVENTORY; PREGNANCY; PREGNANCY OUTCOME; PRENATAL EXPOSURE DELAYED EFFECTS; PROSPECTIVE STUDIES; PSYCHOMETRICS; RISK FACTORS; SEROTONIN UPTAKE INHIBITORS;

EID: 79960743134     PISSN: 01606689     EISSN: None     Source Type: Journal    
DOI: 10.4088/JCP.10m06461     Document Type: Article

References (60)

1. Gaynes BN, Gavin N, Meltzer-Brody S, et al. Perinatal Depression: Prevalence, Screening Accuracy, and Screening Outcomes. Summary, Evidence Report/Technology Assessment No. 119. Rockville, MD: Agency for Healthcare Research and Quality; 2005.
2. Reefhuis J, Rasmussen SA, Friedman JM. Selective serotonin-reuptake inhibitors and persistent pulmonary hypertension of the newborn [comment]. N Engl J Med. 2006;354(20):2188-2190, author reply 2188-2190. doi:10.1056/ NEJMc060602 PubMed
3. Moses-Kolko EL, Bogen D, Perel J, et al. Neonatal signs after late in utero exposure to serotonin reuptake inhibitors: literature review and implications for clinical applications. JAMA. 2005;293(19):2372-2383. doi:10.101/jama.293.19.2372 PubMed (Pubitemid 40676760)
4. Rampono J, Proud S, Hackett LP, et al. A pilot study of newer antidepressant concentrations in cord and maternal serum and possible effects in the neonate. Int J Neuropsychopharmacol. 2004;7(3):329-334. doi:10.1017/S14614570404286 PubMed (Pubitemid 39166467)
5. Källén B. Neonate characteristics after maternal use of antidepressants in late pregnancy. Arch Pediatr Adolesc Med. 2004;158(4):312-316. doi:10.101/archpedi.158.4.312 PubMed (Pubitemid 38451555)
6. Sanz EJ, De-las-Cuevas C, Kiuru A, et al. Selective serotonin reuptake inhibitors in pregnant women and neonatal withdrawal syndrome: a database analysis. Lancet. 2005;365(9458):482-487. PubMed
7. Chambers CD, Johnson KA, Dick LM, et al. Birth outcomes in pregnant women taking fluoxetine. N Engl J Med. 1996;335(14):1010-1015. doi:10.1056/ NEJM19610351402 PubMed
8. Oberlander TF, Warburton W, Misri S, et al. Neonatal outcomes after prenatal exposure to selective serotonin reuptake inhibitor antidepressants and maternal depression using population-based linked health data. Arch Gen Psychiatry. 2006;63(8):898-906. doi:10.101/archpsyc.63.8.898 PubMed (Pubitemid 44188483)
9. Levinson-Castiel R, Merlob P, Linder N, et al. Neonatal abstinence syndrome after in utero exposure to selective serotonin reuptake inhibitors in term infants. Arch Pediatr Adolesc Med. 2006;160(2):173-176. doi:10.101/archpedi.160.2.173 PubMed (Pubitemid 43213863)
10. Laine K, Heikkinen T, Ekblad U, et al. Effects of exposure to selective serotonin reuptake inhibitors during pregnancy on serotonergic symptoms in newborns and cord blood monoamine and prolactin concentrations. Arch Gen Psychiatry. 2003;60(7):720-726. doi:10.101/archpsyc.60.7.720 PubMed (Pubitemid 36818634)
11. Boucher N, Bairam A, Beaulac-Baillargeon L. A new look at the neonate's clinical presentation after in utero exposure to antidepressants in late pregnancy. J Clin Psychopharmacol. 2008;28(3):334-339. doi:10.1097/JCP. 0b013e318173a2e PubMed
12. Boucher N, Koren G, Beaulac-Baillargeon L. Maternal use of venlafaxine near term: correlation between neonatal effects and plasma concentrations. Ther Drug Monit. 2009;31(3):404-409. doi:10.1097/FTD.0b013e3181a58fb4 PubMed
13. Galbally M, Lewis AJ, Lum J, et al. Serotonin discontinuation syndrome following in utero exposure to antidepressant medication: prospective controlled study. Aust N Z J Psychiatry. 2009;43(9):846-854. doi:10.1080/048670903107583 PubMed
14. Reis M, Källén B. Delivery outcome after maternal use of antidepressant drugs in pregnancy: an update using Swedish data. Psychol Med. 2010; 40(10):1723-1733 [epub ahead of print]. doi:10.1017/S032917092194 PubMed
15. Rampono J, Simmer K, Ilett KF, et al. Placental transfer of SSRI and SNRI antidepressants and effects on the neonate. Pharmacopsychiatry. 2009; 42(3):95-100. doi:10.105/s-028-103296 PubMed
16. Hendrick V, Stowe ZN, Altshuler LL, et al. Placental passage of antidepressant medications. Am J Psychiatry. 2003;160(5):993-996. doi:10.176/api.ajp.160.5.93 PubMed (Pubitemid 41079587)
17. Oberlander TFMS, Misri S, Fitzgerald CE, et al. Pharmacologic factors associated with transient neonatal symptoms following prenatal psychotropic medication exposure. J Clin Psychiatry. 2004;65(2):230-237. doi:10.408/JCP. v65n0214 PubMed
18. Haddad PM, Pal BR, Clarke P, et al. Neonatal symptoms following maternal paroxetine treatment: serotonin toxicity or paroxetine discontinuation syndrome? J Psychopharmacol. 2005;19(5):554-557. doi:10.17/0269810505654 PubMed
19. Dubnov-Raz G, Juurlink DN, Fogelman R, et al. Antenatal use of selective serotonin-reuptake inhibitors and QT interval prolongation in newborns. Pediatrics. 2008;122(3):e710-e715. doi:10.1542/peds.208-0658 PubMed
20. Costei AM, Kozer E, Ho T, et al. Perinatal outcome following third trimester exposure to paroxetine. Arch Pediatr Adolesc Med. 2002;156(11): 1129-1132. PubMed
21. Hiemke C, Härtter S. Pharmacokinetics of selective serotonin reuptake inhibitors. Pharmacol Ther. 2000;85(1):11-28. doi:10.1016/S0163-7258(9) 048-0 PubMed
22. Chambers CD, Hernandez-Diaz S, Van Marter LJ, et al. Selective serotonin-reuptake inhibitors and risk of persistent pulmonary hypertension of the newborn. N Engl J Med. 2006;354(6):579-587. doi:10.1056/NEJMoa05274 PubMed (Pubitemid 43209105)
23. Källén B, Olausson PO. Maternal use of selective serotonin re-uptake inhibitors and persistent pulmonary hypertension of the newborn. Pharmacoepidemiol Drug Saf. 2008;17(8):801-806. doi:10.102/pds.1570 PubMed
24. Andrade SE, McPhillips H, Loren D, et al. Antidepressant medication use and risk of persistent pulmonary hypertension of the newborn. Pharmacoepidemiol Drug Saf. 2009;18(3):246-252. doi:10.102/pds.1710 PubMed
25. Wichman CL, Moore KM, Lang TR, et al. Congenital heart disease associated with selective serotonin reuptake inhibitor use during pregnancy. Mayo Clin Proc. 2009;84(1):23-27. doi:10.4065/84.1.23 PubMed
26. Wilson KL, Zelig CM, Harvey JP, et al. Persistent pulmonary hypertension of the newborn is associated with mode of delivery and not with maternal use of selective serotonin reuptake inhibitors. Am J Perinatol. 2011;28(1):19-24. doi:10.105/s-030-1262507 PubMed.
27. Wisner KL, Sit DK, Hanusa BH, et al. Major depression and antidepressant treatment: impact on pregnancy and neonatal outcomes. Am J Psychiatry. 2009;166(5):557-566. doi:10.176/api.ajp.208.0808170 PubMed
28. Li D, Liu L, Odouli R. Presence of depressive symptoms during early pregnancy and the risk of preterm delivery: a prospective cohort study. Hum Reprod. 2009;24(1):146-153. doi:10.1093/humrep/den342 PubMed
29. Bonari L, Pinto N, Ahn E, et al. Perinatal risks of untreated depression during pregnancy. Can J Psychiatry. 2004;49(11):726-735. PubMed
30. Alder J, Fink N, Bitzer J, et al. Depression and anxiety during pregnancy: a risk factor for obstetric, fetal and neonatal outcome? a critical review of the literature. J Matern Fetal Neonatal Med. 2007;20(3):189-209. doi:10.1080/14767050701209560 PubMed (Pubitemid 47221611)
31. King-Hele S, Webb RT, Mortensen PB, et al. Risk of stillbirth and neonatal death linked with maternal mental illness: a national cohort study. Arch Dis Child Fetal Neonatal Ed. 2009;94(2):F105-F110. doi:10.136/adc.207. 135459 PubMed
32. Misra DP, Guyer B, Allston A. Integrated perinatal health framework: a multiple determinants model with a life span approach. Am J Prev Med. 2003;25(1):65-75. doi:10.1016/S0749-3797(03)090-4 PubMed (Pubitemid 36724694)
33. Wadhwa PD, Culhane JF, Rauh V, et al. Stress and preterm birth: neuroendocrine, immune/inflammatory, and vascular mechanisms. Matern Child Health J. 2001;5(2):119-125. doi:10.1023/A:10135321619 PubMed
34. Loughhead AM, Stowe ZN, Newport DJ, et al. Placental passage of tricyclic antidepressants. Biol Psychiatry. 2006;59(3):287-290. doi:10.1016/j.biopsych. 205.06.040 PubMed (Pubitemid 43208977)
35. Oberlander TF, Warburton W, Misri S, et al. Effects of timing and duration of gestational exposure to serotonin reuptake inhibitor antidepressants: population-based study. Br J Psychiatry. 2008;192(5):338-343. doi:10.192/bjp.bp.107.037101 PubMed (Pubitemid 351692377)
36. Warburton W, Hertzman C, Oberlander TF. A register study of the impact of stopping third trimester selective serotonin reuptake inhibitor exposure on neonatal health. Acta Psychiatr Scand. 2010;121(6):471-479. doi:10.1/j.160-047. 209.01490.x PubMed
37. First MB, Spitzer RL, Gibbon M, et al. Structured Clinical Interview for DSM-IV Axis I Disorders-Patient Edition. Washington, DC: American Psychiatric Press; 1996.
38. Post RM, Roy-Byrne PP, Uhde TW. Graphic representation of the life course of illness in patients with affective disorder. Am J Psychiatry. 1988; 145(7):844-848. PubMed
39. Williams JBW, Terman M. Structured Interview Guide for the Hamilton Depression Rating Scale With Atypical Depression Supplement (SIGH-ADS). New York, NY: New York State Psychiatric Institute; 2003.
40. Hamilton M. A rating scale for depression. J Neurol Neurosurg Psychiatry. 1960;23(1):56-62. doi:10.136/jnp.23.1.56 PubMed
41. Ter Horst PG, Jansman FG, van Lingen RA, et al. Pharmacological aspects of neonatal antidepressant withdrawal. Obstet Gynecol Surv. 2008;63(4): 267-279. doi:10.1097/OGX.0b013e3181676be8 PubMed (Pubitemid 351432767)
42. O'Hara MW. Social support, life events, and depression during pregnancy and the puerperium. Arch Gen Psychiatry. 1986;43(6):569-573. PubMed
43. Wisner KL, Perel JM, Peindl KS, et al. Effects of the postpartum period on nortriptyline pharmacokinetics. Psychopharmacol Bull. 1997;33(2): 243-248. PubMed
44. Rochat B, Amey M, Baumann P. Analysis of enantiomers of citalopram and its demethylated metabolites in plasma of depressive patients using chiral reverse-phase liquid chromatography. Ther Drug Monit. 1995;17(3): 273-279. doi:10.1097/07691-195060-01 PubMed
45. Wisner KL, Hanusa BH, Perel JM, et al. Postpartum depression: a randomized trial of sertraline versus nortriptyline. J Clin Psychopharmacol. 2006;26(4):353-360. doi:10.1097/01.jcp.02706.56870.d PubMed (Pubitemid 44187636)
46. Sit DK, Perel JM, Helsel JC, et al. Changes in antidepressant metabolism and dosing across pregnancy and early postpartum. [see comment] J Clin Psychiatry. 2008;69(4):652-658. doi:10.408/JCP.v69n0419 PubMed (Pubitemid 351792342)
47. Sit DK, Perel JM, Luther JF, et al. Disposition of chiral and racemic fluoxetine and norfluoxetine across childbearing. J Clin Psychopharmacol. 2010;30(4):381-386. doi:10.1097/JCP.0b013e3181e7be23 PubMed
48. Brazelton TB. Neonatal Behavioral Assessment Scale. Philadelphia: Lippincott; 1973.
49. Heikkinen T, Ekblad U, Palo P, et al. Pharmacokinetics of fluoxetine and norfluoxetine in pregnancy and lactation. Clin Pharmacol Ther. 2003;73(4):330-337. doi:10.1016/S09-9236(02)17634-X PubMed (Pubitemid 36403593)
50. Scordo MG, Spina E, Dahl ML, et al. Influence of CYP2C9, 2C19 and 2D6 genetic polymorphisms on the steady-state plasma concentrations of the enantiomers of fluoxetine and norfluoxetine. Basic Clin Pharmacol Toxicol. 2005;97(5):296-301. doi:10.1/j.1742-7843.205.pto-194.x PubMed (Pubitemid 41608122)
51. Eap CB, Bondolfi G, Zullino D, et al. Concentrations of the enantiomers of fluoxetine and norfluoxetine after multiple doses of fluoxetine in cytochrome P4502D6 poor and extensive metabolizers. J Clin Psychopharmacol. 2001;21(3):330-334. doi:10.1097/04714-201060-013 PubMed (Pubitemid 32452939)
52. Tracy TS, Venkataramanan R, Glover DD, et al; National Institute for Child Health and Human Development Network of Maternal-Fetal- Medicine Units. Temporal changes in drug metabolism (CYP1A2, CYP2D6 and CYP3A Activity) during pregnancy. Am J Obstet Gynecol. 2005;192(2):633-639. doi:10.1016/j.ajog.204.08. 030 PubMed
53. Wadelius M, Darj E, Frenne G, et al. Induction of CYP2D6 in pregnancy. Clin Pharmacol Ther. 1997;62(4):400-407. doi:10.1016/S09-9236(97)9018-1 PubMed (Pubitemid 27475224)
54. Kearns GL, Abdel-Rahman SM, Alander SW, et al. Developmental pharmacology - drug disposition, action, and therapy in infants and children. N Engl J Med. 2003;349(12):1157-1167. doi:10.1056/NEJMra035092 PubMed (Pubitemid 37122329)
55. Kapur G, Mattoo T, Aranda JV. Pharmacogenomics and renal drug disposition in the newborn. Semin Perinatol. 2004;28(2):132-140. doi:10.1053/j.semperi.203. 1.05 PubMed (Pubitemid 38590914)
56. Wang JS, Newport DJ, Stowe ZN, et al. The emerging importance of transporter proteins in the psychopharmacological treatment of the pregnant patient. Drug Metab Rev. 2007;39(4):723-746. doi:10.1080/03602530701690390 PubMed (Pubitemid 350208727)
57. Ereshefsky L, Dugan D. Review of the pharmacokinetics, pharmacogenetics, and drug interaction potential of antidepressants: focus on venlafaxine. Depress Anxiety. 2000;12(suppl 1):30-44. doi:10.102/1520-6394(20)12:1+<30:AID- DA4>3.0.CO;2-G PubMed
58. Anderson GD. Children versus adults: pharmacokinetic and adverse-effect differences. Epilepsia. 2002;43(suppl 3):53-59. doi:10.1046/j.1528-157.43.s.3.5. x PubMed (Pubitemid 34633697)
59. Lennestål R, Källén B. Delivery outcome in relation to maternal use of some recently introduced antidepressants. J Clin Psychopharmacol. 2007; 27(6):607-613. doi:10.1097/jcp.0b013e31815ac4d2 PubMed (Pubitemid 351339448)
60. Suri R, Altshuler L, Hellemann G, et al. Effects of antenatal depression and antidepressant treatment on gestational age at birth and risk of preterm birth. Am J Psychiatry. 2007;164(8):1206-1213. doi:10.176/api.ajp.207.0607172 PubMed (Pubitemid 47292409)